[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stuttering\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stuttering":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,71,95,122,146,167,195],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643967","noninvasive-thalamocortical-neuromodulation-with-low-intensity-focused-ultrasound-for-persistent-developmental-stuttering-100643967",false,"NCT07668882","Noninvasive Thalamocortical Neuromodulation With Low-Intensity Focused Ultrasound for Persistent Developmental Stuttering","Inclusion Criteria:\n\n* have normal language, hearing and cognition\n* speak English as their primary language\n* currently stutter\n* score at least 10 (very mild) on the Stuttering Severity Instrument (SSI-4) or exhibit greater than 3% stuttered syllables during at least one of the first 3 speech samples\n* have not receive any treatment for stuttering within the past year\n\nExclusion Criteria:\n\n* History of seizures\n* Major medical or neurological illness (e.g., stroke, serious head trauma, brain infection, Parkinson's disease, etc.)\n* History of closed head injury with loss of consciousness (e.g., concussion)\n* Metal or electronic implants such as cochlear implants and pacemakers\n* Braids or other hair styling that prevents direct access to the scalp (if removal not possible)\n* Current or planned pregnancy\n\nNote: participants who cannot undergo MRI may complete the other portions of the study.","ALL","18 Years","65 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This research is studying the use of low-intensity focused ultrasound (LIFU; a mild, noninvasive acoustic stimulation technique) in a small number of people to learn about its safety as a treatment for stuttering. LIFU is a small, safe sound signal that produces a gentle, pulsing flow of acoustic waves to help different parts of the brain communicate with each other. Researchers want to understand how the mild, non-invasive brain stimulation affects speech relevant brain areas, which may in turn affect speech fluency and speaking-related brain activity in people who stutter.",[26,27],"Stuttering","Developmental Stuttering",[29,30,31],"Low Intensity Focused Ultrasound","Thalamus","Neuromodulation","NOT_YET_RECRUITING","2026-06-19",{"date":35,"type":36},"2026-06-25","ACTUAL",{"date":38,"type":20},"2026-06",{"date":40,"type":20},"2027-06",{"name":42,"class":43},"University of Michigan","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100606828","organization-and-development-of-motor-cortical-circuits-for-speech-production-in-stuttering-100606828","NCT07180628","Organization and Development of Motor Cortical Circuits for Speech Production in Stuttering","Inclusion Criteria:\n\n* Are between the ages of 18-65 years\n* Have otherwise normal speech, language, hearing and cognition\n* Speak English as their primary language\n* Currently stutter\n\nExclusion Criteria:\n\n* Have serious medical or neurological conditions (e.g., stroke, traumatic brain injury, Parkinson's disease, etc.)\n* Have had a closed head injury (e.g., concussion)\n* Have a reading disorder (e.g., dyslexia)\n* Have hearing loss\n* Have metal or electronic implants (e.g., cochlear implants, pacemakers, etc.)\n* Are currently pregnant",{"count":52,"type":20},50,[23],"The overall objective of this study is to examine inter effector areas (IEAs) activity and functional connectivity during continuous speech production in stuttering adults.",[56,57,26,58],"Stutter","Stuttering, Adult","Stuttering, Developmental",[60,61],"Magnetic Resonance Imaging (MRI) scans","Behavioral assessments","RECRUITING","2026-04-27",{"date":65,"type":36},"2026-04-29",{"date":67,"type":36},"2026-04-24",{"date":69,"type":20},"2029-03",{"name":42,"class":43},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":15,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":93,"locationsCount":44},"100560535","the-development-of-stuttering-in-young-children-100560535","NCT06578416","The Development of Stuttering in Young Children","Developmental Trajectories to Stuttering Persistence and Recovery","Inclusion Criteria for controls:\n\n* English as first\u002Fprimary language\n* No history of neurological disease\n* Normal or corrected visual acuity\n* No medications expected to affect performance\n* No intellectual impairment, autism spectrum disorder, ADHD\n* Age-appropriate scores on speech and language assessment battery\n* Pass hearing screening at 20 dB at 500, 1000, 2000, and 4000, bilaterally\n\nInclusion Criteria for children who stutter:\n\n* English as first\u002Fprimary language\n* No history of neurological disease\n* Normal or corrected visual acuity\n* No medications expected to affect performance\n* No intellectual impairment or ASD Scores on speech and language assessments indicating stuttering, phonological (speech sound), or language disorders\n* Pass hearing screening at 20 dB at 500, 1000, 2000, and 4000, bilaterally",true,"3 Years","6 Years",{"count":82,"type":20},120,"OBSERVATIONAL","The goal of this longitudinal research is to learn why some children \"grow out\" of stuttering, while others persist. Children who do and do not stutter aged 3-6 years are eligible to participate in our study. During the study, children's speech and language abilities will be assessed with standardized assessments, and they complete several child-friendly experiments. During these experiments, brain activity will be recorded using specialized caps while children describe pictures, children will speak in two virtual-reality scenarios, and produce speech while keeping to a beat.",[26,86,58],"Stuttering, Childhood","2026-04-13",{"date":89,"type":36},"2026-04-16",{"date":91,"type":36},"2023-06-01",{"date":40,"type":20},{"name":94,"class":43},"Michigan State University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":15,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":44},"100620170","using-non-invasive-brain-stimulation-to-explore-potential-treatments-to-reduce-speech-errors-in-adults-who-stutter-100620170","NCT07354139","Using Non-invasive Brain Stimulation to Explore Potential Treatments to Reduce Speech Errors in Adults Who Stutter","Examining Speech Production Errors in Stuttering Through High Definition - Transcranial Direct Current Stimulation","Inclusion Criteria:\n\n* Must be 22 years old or older\n* May be bi\u002Fmultilingual but must speak English as dominant language.\n* Must be diagnosed or suspected of developmental stuttering disorder. Participants will be administered the Stuttering Severity Instrument 4 and categorized as typical speakers or mild, moderate, or severe stutterers.\n* Must be able to attend the session at the physical location within the clinic\n\nExclusion Criteria:\n\n* Patients with preexisting speech\u002Flanguage disorders or previously diagnosed neurological disorders (including but not limited to apraxia of speech, cerebral palsy, dysarthria, tourettes, or any other neurological\u002Fmotor condition) that affect speech\u002Flanguage (except stuttering) are excluded to minimize the interference of atypical brain activity.\n* Participants who have acquired or neurogenic stuttering (stuttering resulting from a brain injury) are excluded, as this study focuses exclusively on the effects of developmental stuttering.\n* Participants with a history of seizures\n* Participants with unexplained episodes of loss of consciousness, since such condition could be related with brain alterations or epilepsy\n* Participants with unstable or non controlled neuropsychiatric illness\n* Participants having implanted brain medical devices\n* Participants with implanted pacemakers\n* Participants having any electrically,magnetically or mechanically activated implant\n* Participants having cardiac, neural or medication implants\n* Participants having vascular clips or any other electrically sensitive support system in the brain\n* Participants with serious brain injury\n* Participants showing damage of skin at sites of stimulation (the device can only be used in healthy skin without wounds, otherwise the resistance to current can be altered)\n* Participants suffering from skin problems, such as dermatitis, psoriasis or eczema\n* Participants suffering from severe or frequent headaches\n* Participants with any serious life-threatening disease such as congestive heart failure, pulmonary obstructive chronic disease, or active neoplasia\n* Pregnant women\n* Participants may not consume alcohol or controlled substances within 24 hours of the scheduled appointment\n\nParticipants will complete an additional screener upon enrollment to assess medical history and current drug\u002Fmedication use that may conflict with the study.","22 Years",{"count":52,"type":20},[23],"The goal of this study is to find out whether a type of noninvasive brain stimulation can help reduce speech errors, such as repetitions, blocks, and prolongations, in people who stutter. This pilot study will help researchers design future treatments to see if targeting certain brain areas can improve speech fluency. The study will look at how people speak and behave during both speaking and non-speaking tasks before and after the brain stimulation.\n\nParticipants will complete an online survey about 24 hours before coming to the clinic. The clinic visit will last about 3 hours and will include three phases. All parts of the study will be audio-recorded.\n\n1. Pre-Testing: Participants will first complete a stuttering evaluation to determine whether they are typical speakers or have a mild, moderate, or severe stutter. Then, they will do several speaking and non-speaking tasks.\n2. Brain Stimulation: Participants will receive a session of targeted noninvasive brain stimulation (HD-tDCS).\n3. Post-Testing: After the brain stimulation, participants will repeat the same evaluation and tasks they completed during pre-testing.\n\nBrain stimulation description:\n\nHD-tDCS is a non-invasive technique that requires the placement of several sensors (metal electrodes) on a special cap and saline gel on your head. Very low levels of constant electrical current are delivered to specifically targeted areas of the brain via these electrodes. You may experience a slight feeling of dizziness when starting the stimulation. This occurs in a small number of subjects. This takes only a few seconds and does not affect balance after the stimulation has been completed. Several research centers have previously investigated the use of this device on healthy subjects and have found the device to be safe with no direct effect on the person's well-being. Following stimulation, participants will have the opportunity to rinse out residual gel from hair and scalp.",[26,107],"Fluency Disorder",[26,109,110,111,112],"HD-tDCS","neuromodulation","speech","fluency","2026-04-08",{"date":115,"type":36},"2026-04-14",{"date":117,"type":36},"2026-03-17",{"date":119,"type":20},"2026-09-30",{"name":121,"class":43},"The University of Texas at Dallas",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":133,"conditions":134,"keywords":135,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":44},"100615724","phase-2-effects-of-psilocybin-on-speech-fluency-struggle-and-brain-activity-in-people-who-stutter-100615724","NCT07296328","Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter","Inclusion Criteria:\n\n* Are able to provide voluntary informed consent\n* Are able to read, speak, and understand English, as documented during the informed consent process.\n\n  o Non-English-speaking subjects will be excluded because the study is using only validated English-language versions of assessment instruments.\n* Are 18 to 50 years old, inclusive, at Screening visit.\n* Have diagnosis of mild-moderate to severe stuttering based on either the SSI-4 or OASES; also confirmed stuttering by stuttering specialist.\n* Are able and willing to adhere to all study requirements, including attending all study visits and therapy sessions, and completing all assessments.\n* Agree to refrain from any non-prescribed psychotropic substance or illicit drug use for at least 72 hours prior to investigational product (IP) administration, and for at least 24 hours before each fMRI assessment visit, with the exceptions of nicotine and caffeine. Regarding nicotine, they must agree not to use nicotine for at least 1 hour before and 6 hours following IP administration, and for at least 1 hour before fMRI scans. Regarding caffeine, they must agree to consume approximately their usual amount of caffeine on the morning of Day 0 (prior to IP administration).\n* Agree to refrain from taking all non-prescription medications and supplements (nutritional and herbal) for at least 1 week prior to the IP administration session unless approved by the Investigator.\n* Can swallow capsules.\n* Subjects who are able to become pregnant must comply with the following conditions:\n\nA. Subjects are considered able to become pregnant unless they\n\n1. Do not have a uterus;\n2. Are postmenopausal (has had 12 months of natural amenorrhea with a matching clinical profile \\[age, history of vasomotor symptoms\\]) prior to Screening Part 2; or\n3. Are surgically sterile (documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).\n\nB. Subjects who are able to become pregnant must\n\n1. Have a negative pregnancy test at Screening (Reassessed at Day 0 (pre-IP administration);\n2. Not be currently breastfeeding;\n3. Not intend to become pregnant during participation in this study;\n4. Agree to use a highly effective form of contraception from the time of Screening until 7 days after the IP Administration Session. Highly effective forms of contraception include:\n\n   1. Consistent and correct usage of established oral contraception;\n   2. Injected or implanted hormonal methods of contraception;\n   3. Established intrauterine device or intrauterine system;\n   4. Bilateral tubal ligation;\n   5. Intercourse with a partner who has undergone effective surgical sterilization, provided that partner is the sole sexual partner of the study subject;\n   6. Abstinence from penile\u002Fvaginal intercourse, if the Investigator determines that the subject can reliably adhere to the plan, based on evaluation of the participant's preferred and usual lifestyle and social circumstances.\n5. Agree not to donate or bank eggs from the time of Screening Part 2 until 7 days after the IP Administration Session.\n\nIf able to become pregnant or produce viable sperm (male or female), are willing to use approved contraception for duration of the trial.\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Any medical condition that would preclude safe participation in the study, including the following, as determined by medical history review, physical examination, electrocardiogram (ECG), and clinical laboratory tests:\n\n  * Seizure disorder\n  * Significantly impaired liver function, defined as 1) alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 5 × upper limit of normal (ULN); 2) ALT or AST \\> 3 × ULN with concomitant total bilirubin \\> 2.0 × ULN; or 3) ALT or AST ≥ 3 × ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and\u002For eosinophilia.\n  * Cardiovascular disease including coronary artery disease, angina, history of arrhythmia (unless a successful ablation has been performed), heart failure, history of heart valve replacement, and history of cerebrovascular accident or transient ischemic attack.\n  * Uncontrolled hypertension with systolic blood pressure \\> 140 mmHg or diastolic blood pressure \\> 90 mmHg. (Note: participants who otherwise meet all eligibility criteria during the screening visit will have 3 opportunities to produce 1 blood pressure reading ≤ 140\u002F90 mmHg (each reading will be collected at least 15 minutes apart). If blood pressure at Screening is consistently elevated (\\> 140\u002F90 mmHg across all 3 attempts), participants may be referred to their primary care provider (PCP) for management of hypertension. Participants may continue study participation if the Investigator believes that it is likely that hypertension can be controlled prior to the IP administration session, and the patient is able to provide documentation of adequate control (BP \\\u003C 140\u002F90 mmHg) prior to the PI administration session.)\n  * Resting heart rate \\> 100 bpm (Note: participants will have an opportunity to return once within the 30-day screening window to make 3 additional attempts at a resting heart rate ≤ 100 bpm.).\n  * Serious ECG abnormalities (e.g., evidence of ischemia, myocardial infarction, QT interval corrected for heart rate \\[QTc\\] prolongation (QTc \\> 0.450 seconds), arrhythmia, or conduction abnormalities that increase the risk of arrhythmia.\n  * Hyperthyroidism\n  * Insulin-dependent diabetes\n  * Bradycardia (e.g., heart rate \\\u003C50 bpm)\n  * Orthostatic hypotension\n  * Schizotypal and paranoid personality disorders\n  * Given potential use of diazepam as an ancillary medication, moderate or greater hepatic impairment (Child-Pugh score ≥ 7) is exclusionary.\n  * Any other medical condition which precludes safe participation in the study in the medical opinion of the Investigator. (Note: medical history will be updated on Day 0. Those not meeting the criterion may be rescheduled once within 14 days if the criterion is likely to resolve within 14 days in the judgement of the Investigator.)\n* Have any of the following Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) psychiatric disorders, as determined by the Mini International Neuropsychiatric Interview (MINI) and Psychiatric History at the Screening Visit: (Note: psychiatric history will be re-evaluated on Day 0, but the MINI will not be re-administered on Day 0)\n\n  * Lifetime history of schizophrenia spectrum or other psychotic disorder (including substance or medication-induced psychosis or psychosis due to a co-occurring medical condition).\n  * Major depressive disorder (MDD)Post traumatic stress disorder (PTSD)\n  * Cluster B personality disorders (antisocial personality disorder, borderline personality disorder, histrionic personality disorder, and narcissistic personality disorder)\n  * Bipolar I disorder, Bipolar II disorder, and Cyclothymic disorder\n* Have active suicidal ideation with intent, based on Columbia-Suicide Severity Rating Scale (C-SSRS) assessment (severity score \\> 3) at the Screening visit, confirmed by the Investigator. (Note: this criterion will be reassessed at each visit that occurs prior to Day 0, and on Day 0. Participants will be discharged if actively suicidal, and appropriate follow-up will be arranged.\n* Have made a medically significant suicide attempt (i.e., one that had a significant possibility of causing death or permanent harm in the absence of intervention) within the past 12 months, based on Screening C-SSRS assessment and confirmation by the Investigator. (Note: this criterion will be reassessed at each visit that occurs prior to Day 0, and on Day 0. Participants will be discharged if actively suicidal, and appropriate follow-up will be arranged.)\n* Have a family history (first degree relatives) of schizophrenia, schizoaffective disorder, or bipolar disorder type 1.\n* Have a history of hallucinogen use disorder.\n* Have a history of hallucinogen persisting perceptual disorder (HPPD).\n* Have any use of classic psychedelics in the past 1 year.\n* Have \\> 25 lifetime uses of classic psychedelics.\n* Incarcerated or have pending legal action that could prevent participation in study activities.\n* Are unable or unwilling to discontinue taking any protocol-prohibited medications and supplements. (A detailed list of exclusionary medications is found in Section 6.5 of the protocol.) Prohibited medications and supplements must have been stopped for at least 5 elimination half-lives or 14 days, whichever is longer, prior to Day 0 (Note: Psychiatric medications will not be discontinued or changed in order to allow study participation. Concomitant medications will be reassessed on Day 0. Any patient who has started prohibited medications will be discharged from the study.)\n* Have a known allergy or hypersensitivity to psilocybin or any of the materials contained in the IP used in the study.\n* Have an allergy, hypersensitivity, or other contraindication that would preclude safe treatment of acute hypertension, anxiety, or psychotic symptoms if necessary, during or immediately after the IP Administration Session, using the adjunctive medications used in this pilot study to treat these symptoms (i.e., unable to take captopril and unable to take clonidine; unable to take diazepam; or unable to take olanzapine).\n* Have any other medical, psychiatric, or psychosocial disorder, symptom, condition, or situation that is likely to interfere with the establishment of rapport, adherence to study requirements, or safe administration of psilocybin or functional magnetic resonance imaging (fMRI) scanning, based on the judgement of the Investigator. (Note: This criterion will be reassessed on Day 0. Those not meeting the criterion will not be randomized but may be rescheduled once within 14 days if the criterion is likely to resolve within 14 days in the judgement of the Investigator.)\n* Inability to safely complete fMRI sessions (MRI screening form)\n* Any history of severe traumatic brain injury (assessed using the Ohio State University Traumatic Brain Injury Identification Method (OSU TBI-ID) modified). (Note: If current (past 12 months) mild\u002Fmoderate Traumatic Brain Injury (TBI) and Central Sensitization Inventory (CSI) score \\>\u002F= 12 (for either lifetime month or current month), the PI will determine eligibility.)","50 Years",{"count":130,"type":20},25,[132],"PHASE2","This Phase 2a clinical trial is an open-label, single-group, within-subjects pilot study designed to evaluate the safety, feasibility, and preliminary efficacy of psilocybin as a therapeutic intervention for adults with developmental stuttering. This pilot study will assess whether further research to explore the potential benefits of psilocybin-assisted therapy for improving clinical outcomes in individuals who stutter, is warranted. The aims of this study include:\n\n* Aim 1: Assess the safety and feasibility of psilocybin as a therapeutic agent for stuttering.\n* Aim 2: Evaluate the effects of psilocybin on objective and subjective measures of stuttering severity, struggle, and well-being.\n* Aim 3: Explore the therapeutic neural mechanisms of psilocybin in stuttering.",[26],[26,136,56],"Psilocybin","2025-12-18",{"date":139,"type":36},"2025-12-22",{"date":141,"type":20},"2026-01-15",{"date":143,"type":20},"2027-04-01",{"name":145,"class":43},"NYU Langone Health",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":152,"targetDuration":4,"studyType":21,"phases":154,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":44},"100610021","stuttering-and-neuromodulation-100610021","NCT07222163","Stuttering and Neuromodulation","Inclusion Criteria:\n\n1. Adults aged 18 to 65 years.\n2. Diagnosis of developmental stuttering, verified by a licensed speech-language pathologist.\n3. Mild-to-moderate or greater stuttering severity, defined as a score of 20 or higher on the Stuttering Severity Instrument-Fourth Edition (SSI-4).\n4. English as a primary language.\n5. Right-handedness (to minimize variability in neural lateralization).\n6. Willing and able to attend all study sessions and follow study procedures.\n\nExclusion Criteria:\n\n1. Have a history of neurological, psychiatric, or medical conditions that are contraindicated for tDCS.\n2. Are currently taking medications known to affect cortical excitability.\n3. Have a history of seizures or epilepsy.\n4. Are pregnant or planning to become pregnant during the study period.\n5. Have metal implants in the head (excluding dental work) or other contraindications to electrical brain stimulation.\n6. Any skin disorder or skin sensitive area near stimulation locations.",{"count":153,"type":20},16,[23],"The purpose of this study is to collect preliminary data on the efficacy of transcranial direct current stimulation (tDCS) combined with traditional behavioral techniques to reduce stuttering severity and negative impact in adults who stutter. The study also aims to explore neuroplastic changes (i.e., regional activation and functional connectivity) resulting from combined tDCS + speech therapy.",[26],[158],"tDCS","2025-10-28",{"date":161,"type":36},"2025-10-29",{"date":163,"type":36},"2025-09-04",{"date":165,"type":20},"2027-10",{"name":145,"class":43},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":78,"sex":15,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":44},"100461247","network-connectivity-and-temporal-processing-in-adolescents-who-stutter-100461247","NCT05286151","Network Connectivity and Temporal Processing in Adolescents Who Stutter","Subcortical Network Connectivity and Temporal Processing in Children With Persistent and Recovered Stuttering","Inclusion Criteria Children who stutter:\n\n* English as primary language\n* Current or past stuttering diagnosis\n\nInclusion Criteria Children who do not stutter:\n\n* English as primary language\n\nExclusion Criteria Children who stutter:\n\n* Diagnosed\u002Funder treatment for any neurological or psychiatric conditions\n* Head trauma with loss of consciousness\n* Major medical illness\n* Hearing loss- Language\u002Fmotor delay (below -2 standard deviations on standardized assessments)\n* Face, motor, or reflex abnormalities\n\nExclusion Criteria Children who do not stutter:\n\n* Personal or family history of stuttering\n* Diagnosed\u002Funder treatment for any neurological or psychiatric conditions\n* Head trauma with loss of consciousness\n* Major medical illness\n* Hearing loss\n* Language\u002Fmotor delay (below -2 standard deviations on standardized assessments\n* Face, motor, or reflex abnormalities","9 Years","13 Years",{"count":177,"type":20},500,[23],"The specific purpose of this clinical trial is to compare performance on rhythm perception and production tasks between children who stutter and children who do not stutter. The overall project also aims to investigate how performance on rhythm tasks may be related to brain activity (non-clinical trial).",[86,26],[182,183,184,185,186],"Rhythm","Temporal processing","Healthy children","Speech disorders","Timing","2025-10-21",{"date":189,"type":36},"2025-10-23",{"date":191,"type":36},"2022-07-23",{"date":193,"type":20},"2027-01-31",{"name":42,"class":43},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":78,"sex":15,"minAge":202,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":21,"phases":206,"briefSummary":207,"conditions":208,"keywords":209,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":44},"100509030","exploring-the-nature-assessment-and-treatment-of-stuttering-100509030","NCT05908123","Exploring the Nature, Assessment and Treatment of Stuttering","The Blank Center CARE Model™: An Anti-Ableist Approach to Treatment","Inclusion Criteria:\n\nA participant will be considered a child who stutters (ages 2-17 years) if\n\n* their parent\u002Fcaregiver reports concern that their child is a person who stutters,\n* they exhibit three of more stuttering-like disfluencies (e.g., sound\u002Fsyllable repetitions, (in)audible sound prolongations, whole-word repetitions) per 300-word speech sample, or\n* they present with an overall score of 11 or higher on the Stuttering Severity Instrument - 4th Edition (SSI-4).\n\nA participant will be considered an adult who stutters (18+ years) if\n\n* they report they are a person who stutters,\n* they have received a formal diagnosis of stuttering from a certified speech-language pathologist,\n* they exhibit three of more stuttering-like disfluencies (e.g., sound\u002Fsyllable repetitions, (in)audible sound prolongations, whole-word repetitions) per 300-word speech sample, or\n* they present with an overall score of 11 or higher on the Stuttering Severity Instrument - 4th Edition (SSI-4).\n\nExclusion Criteria:\n\n• There are no exclusion criteria for persons who stutter.","2 Years","85 Years",{"count":205,"type":20},3000,[23],"The purposes of this study are to 1) investigate potential speech, language, and psychosocial contributions to the experience of stuttering in monolingual and multilingual speakers, and to 2) evaluate interdisciplinary, telehealth, and speech-language pathology treatment methods and clinical training specific to fluency disorders.",[26,57,86,58],[210],"stuttering, communication competence, adult, treatment","2023-06-20",{"date":213,"type":36},"2023-06-22",{"date":215,"type":36},"2015-05-22",{"date":217,"type":20},"2035-05-22",{"name":219,"class":43},"University of Texas at Austin"]